Clinical trial NCT00820352: Safety and Efficacy of Bosentan in Patients With Diastolic Heart Failure and Secondary Pulmonary Hypertension
Official title: Endothelin Receptor Blockade in Heart Failure With Diastolic Dysfunction and Pulmonary Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Heart Failure, Diastolic
Hypertension, Pulmonary
Keywords: HFNEF
HFPEF
Secondary Pulmonary Hypertension
Endothelin Receptor Blockade
Lead sponsor: University Teaching Hospital Hall in Tirol
Sponsor class: OTHER
First posted: 2009-01-12
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Heart failure is a major medical and socioeconomic problem in western industrial countries, especially with aging populations. Heart failure with normal left ventricle systolic function (heart failure with preserved ejection fraction, HFPEF, heart failure with normal ejection fraction, HFNEF) are common causes of hospitalization mainly in the elderly population and are frequently associated with pulmonary hypertension. It is commonly seen, that patients with left heart disease and pulmonary hypertension with right ventricle dysfunction have a worse prognosis.

The investigators hypothesize, that an additional treatment with Bosentan in this patients will improve their exercise capacity, symptoms, hemodynamics and quality of life.

Detailed description: Heart Failure with preserved ejection fraction is with more than 50% of cases the most common form of heart failure. Typically patients are elderly women with arterial hypertension. Mortality, hospitalization rates due to heart failure and in-hospital complications do not differ significantly from patients with systolic heart failure. However there are some subgroups of HFPEF-patients with a worse prognosis, for example up to 30% of patients develop secondary pulmonary hypertension and thus right ventricle dysfunction. Increased right-ventricle systolic pressure is associated with increased mortality in patients with all forms of heart failure.

There is a lack of evidence about HFPEF. Drugs for treating systolic heart failure showed no improvement in mortality and prognosis. Diuretics are just able to relieve symptoms. There are no clinical trials concerning HFPEF with secondary pulmonary hypertension.

The endothelin system is not only activated in PAH, but also in pulmonary venous hypertension and congestive heart failure, where ET-1 levels rise with the severity of secondary pulmonary hypertension. Pulmonary congestion leads to endothelial dysfunction that results in increased levels of Endothelin-1 (ET-1).

ET-1 is a potent vasoconstrictor. In pulmonary arterial vessels the ETA receptor is the predominant receptor (ratio of ETA to ET B = 9:1), which is responsible for vasoconstriction and remodeling of the pulmonal vasculature. In heart failure the ETA receptor is upregulated. Elevated plasma ET-1 levels correlate with pulmonary artery pressure (PAP), pulmonary vascular resistance (PVR) and inversely with peak exercise capacity.

Recent clinical and laboratory findings indicate comparable pathophysiological mechanisms in pulmonary hypertension secondary to left ventricular dysfunction and pulmonary arterial hypertension. Yet, despite an expanding application in pulmonary artery hypertension, according to current opinion, the oral dual endothelin (ETA/ETB) antagonist bosentan is not indicated for PVH caused by left ventricle / left atrial pressure overload and preserved systolic function. However, there are several studies which show some effects of pulmonary vessel dilating drugs in PAH and left ventricle dysfunction.

Eligibility criteria: Inclusion Criteria:

* Clinically signs or history of congestive heart failure NYHA II-III (Fatigue, dyspnea on exertion, lung crepitations, pulmonary edema, ankle and or lower leg swelling, jugular pressure enhancement, hepatomegaly)
* Echocardiographic signs of diastolic dysfunction (heart failure with normal ejection fraction)
* Right ventricle enlargement with pulmonary hypertension
* 6 minute walking distance \> 150 m \< 400 m
* Right Heart Catheterization: Mean PAP \> 25 mmHg, PCWP \> 15 mmHg

Echocardiographic requirements for definition of heart failure with normal ejection fraction

* E/E' \> 15, or
* E/E' \> 8 + NTpBNP \> 220 pg/ml, or
* E/E' \> 8 + E:A \< 0.5 + DT \> 280 ms or
* Ard-Ad \> 30 ms or
* atrial enlargement or
* atrial fibrillation
* NTpBNP \> 220 pg/ml + combination
* IVRT - IVRTm \< 0 septal und lateral

Echocardiographic requirements for pulmonary hypertension and right ventricle dysfunction

* RVEDD \> 30 mm short axis parasternal, and
* one of the following:

  * Tricuspid valve regurgitation velocity (TRV) \> 3 m/s;
  * RV-annular systolic velocity \< 10 cm/sec (TDI)
  * TAPSE \< 18 mm

Exclusion Criteria:

* Patients who are not on guideline conform treatments for cardiovascular disease.
* Left ventricle systolic dysfunction (EF \< 50 %), aortic stenosis with peak gradient (instantane) \> 40 mm Hg,moderate and severe aortic insufficiency
* moderate and severe mitral regurgitation,
* acute coronary disease, stable coronary artery disease or peripheral vascular disease limiting exercise.
* Other causes of pulmonary - artery - hypertension:

  * relevant obstructive ventilatory disease \> grade II (lung functions tests)
  * collagen disease (Tests: MSCT and ANA, ANCA),
  * chronic thrombo- embolic pulmonary arterial hypertension (MSCT),
  * sleep disorder.
  * HIV, HCV, HBV infection.
  * Drug related PAH.
* Orthopaedic disease, immobility, inability to perform 6MWT and cancer.
* Liver disease Child-Pugh B and C, three fold above normal elevated liver enzymes,
* anaemia Hb \< 10 mg/dl,
* other specific treatment of pulmonary arterial hypertension including other endothelin receptor blockers, phosphodiesterase inhibitors, prostaglandins and L-arginin
* drug therapy with glibenclamide, rifampicin, tacrolimus, sirolimus, cyclosporine A
* known adverse reactions to bosentan and
* pregnancy and lactation

Primary outcomes:
measure: change in 6 minute waling distance after 12 weeks of bosentan (or placebo) treatment
timeFrame: 12 weeks
Secondary outcomes:
measure: change in 6 minute walking distance after 24 weeks (12 weeks bosentan or placebo treatment and 12 weeks follow-up)
timeFrame: 24 weeks
measure: changes in hemodynamics assessed by echocardiography after 12 and 24 weeks
timeFrame: 24 weeks
measure: time to clinical worsening after 12 and 24 weeks
timeFrame: 24 weeks
measure: levels of NTpBNP, CRP and Endothelin-1 after 12 and 24 weeks
timeFrame: 24 weeks
measure: Quality of Life assessment (SF-36 and Minnesota Living With Heart Failure Score) after 12 and 24 weeks
timeFrame: 24 weeks
measure: Adverse event count after 12 and 24 weeks
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Waidhofen
country: Austria
facility: Hospital Mostviertel Waidhofen/Ybbs
state: Lower Austria
city: Hall i. T.
country: Austria
facility: University Teaching Hospital Hall i.T.
state: Tyrol
city: Linz
country: Austria
facility: University Teaching Hospital of the Elisabethinen, Linz
state: Upper Austria
city: Wels
country: Austria
facility: Hospital Wels/Grieskirchen
state: Upper Austria
city: Hohenems
country: Austria
facility: Hospital Hohenems
city: Natters
country: Austria
facility: Hospital Natters
city: Salzburg
country: Austria
facility: University Hospital Salzburg
Study officials:
affiliation: University Teaching Hospital Hall i.T.
name: Wilhelm Grander, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kjaergaard J, Akkan D, Iversen KK, Kjoller E, Kober L, Torp-Pedersen C, Hassager C. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol. 2007 Apr 15;99(8):1146-50. doi: 10.1016/j.amjcard.2006.11.052. Epub 2007 Mar 8.
citation: Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006 Jul 20;355(3):251-9. doi: 10.1056/NEJMoa052256.
citation: Shah SJ, Gheorghiade M. Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA. 2008 Jul 23;300(4):431-3. doi: 10.1001/jama.300.4.431. No abstract available.
citation: Sanderson JE. Heart failure with a normal ejection fraction. Heart. 2007 Feb;93(2):155-8. doi: 10.1136/hrt.2005.074187. Epub 2005 Dec 30.
citation: Yip GW, Wang M, Wang T, Chan S, Fung JW, Yeung L, Yip T, Lau ST, Lau CP, Tang MO, Yu CM, Sanderson JE. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008 May;94(5):573-80. doi: 10.1136/hrt.2007.117978. Epub 2008 Jan 20.
citation: Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006 Jul 20;355(3):260-9. doi: 10.1056/NEJMoa051530.
citation: Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL. Systolic and diastolic heart failure in the community. JAMA. 2006 Nov 8;296(18):2209-16. doi: 10.1001/jama.296.18.2209.
citation: Tribouilloy C, Rusinaru D, Mahjoub H, Souliere V, Levy F, Peltier M, Slama M, Massy Z. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J. 2008 Feb;29(3):339-47. doi: 10.1093/eurheartj/ehm554. Epub 2007 Dec 22.
citation: Sweitzer NK, Lopatin M, Yancy CW, Mills RM, Stevenson LW. Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (> or =55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (<40%) fractions. Am J Cardiol. 2008 Apr 15;101(8):1151-6. doi: 10.1016/j.amjcard.2007.12.014. Epub 2008 Feb 20.
citation: Onishi K, Ohno M, Little WC, Cheng CP. Endogenous endothelin-1 depresses left ventricular systolic and diastolic performance in congestive heart failure. J Pharmacol Exp Ther. 1999 Mar;288(3):1214-22.
citation: Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation. 2000 Oct 3;102(14):1718-23. doi: 10.1161/01.cir.102.14.1718.
citation: Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007 Oct 2;116(14):1555-62. doi: 10.1161/CIRCULATIONAHA.107.716373. Epub 2007 Sep 4.
citation: Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004 Feb 1;61(2):227-37. doi: 10.1016/j.cardiores.2003.11.026.
citation: Cowburn PJ, Cleland JG. Endothelin antagonists for chronic heart failure: do they have a role? Eur Heart J. 2001 Oct;22(19):1772-84. doi: 10.1053/euhj.2000.2557. No abstract available.
citation: Cowburn PJ, Cleland JG, McDonagh TA, McArthur JD, Dargie HJ, Morton JJ. Comparison of selective ET(A) and ET(B) receptor antagonists in patients with chronic heart failure. Eur J Heart Fail. 2005 Jan;7(1):37-42. doi: 10.1016/j.ejheart.2004.08.001.
citation: Opitz CF, Ewert R, Kirch W, Pittrow D. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J. 2008 Aug;29(16):1936-48. doi: 10.1093/eurheartj/ehn234. Epub 2008 Jun 17.
citation: Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006 Jul 4;114(1):48-54. doi: 10.1161/CIRCULATIONAHA.106.630715. Epub 2006 Jun 26.
citation: Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 Mar 21;346(12):896-903. doi: 10.1056/NEJMoa012212.
citation: Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, Tapson VF, Rubin LJ. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003 Jul;124(1):247-54. doi: 10.1378/chest.124.1.247.
citation: Zolk O, Quattek J, Sitzler G, Schrader T, Nickenig G, Schnabel P, Shimada K, Takahashi M, Bohm M. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation. 1999 Apr 27;99(16):2118-23. doi: 10.1161/01.cir.99.16.2118.